Low HDL-cholesterol (HDL-C) levels may elevate atherosclerosis risk, and often associate with hypertriglyceridemia (HTG); however, the metabolic causes of low HDL-C levels with or without HTG are poorly understood. We studied the turnover of radioiodinated HDL apolipoproteins, apo A-I and apo A-II, in 15 human subjects with low HDL-C, six with normal plasma TG levels (group 1) and nine with high TG (group 2), and compared them to 13 control subjects with normal HDL-C and TG levels (group 3). The fractional catabolic rate (FCR) was equally elevated in groups 1 and 2 vs. 
1. Abbreviations used in this paper: FCR, fractional catabolic rate; HDL-C, high-density lipoprotein cholesterol; HL, hepatic lipase, HTG, hypertriglyceridemia; LPL, lipoprotein lipase; TG, triglyceride; TR, transport rate.
linked to elevated risk of atherosclerosis (1, 2) ; however, the metabolic mechanisms underlying a low HDL-C are unclear. Previous HDL turnover studies of patients with low HDL-C levels and hypertriglyceridemia (HTG) have shown an elevated fractional catabolic rate (FCR) of the major HDL apolipoproteins apo A-I (3) and apo A-Il (3, 4) . It was concluded that HTG itself was the cause of the low HDL-C level and the increase in HDL apolipoprotein FCR, yet these studies lacked the crucial comparison group ofpatients with low HDL-C and normal TG levels. Only one HDL turnover study has directly compared low HDL-C patients with normal or high TG (5) . In that study, the low-HDL-C, normal TG subjects had normal apo A-I FCR but low TR, whereas the low-HDL-C, HTG subjects had elevated apo A-I FCR and TR. This implied a striking contrast in the metabolism of apo A-I between low-HDL-C patients with or without HTG. Because the comparison groups were small, however, and there was relatively little control over the subjects' diets during the study, we have chosen to reexamine this important issue.
In the current report, we have studied the turnover of apo A-I and apo A-II on a standard 42% fat diet under metabolic ward conditions in 15 subjects with low-HDL-C and normal or high-plasma TG compared to 13 control subjects with normal HDL-C and TG levels. We find that elevated HDL apolipoprotein FCR is the major metabolic mechanism of low HDL-C levels in both normal-TG and HTG subjects, suggesting that HTG is not a unique cause of the elevated FCR. Rather, we find that HTG is one of several factors that combine, possibly in an additive manner, to account for the increased FCR in patients with low HDL-C levels.
Methods
Subjects. 12 male and 16 female subjects were recruited for HDL metabolic studies from three sources: (a) patients from the clinic of the Laboratory of Biochemical Genetics and Metabolism; (b) healthy, adult volunteers working on the staff at Rockefeller University or at neighboring institutions; (c) undergraduate students in a work-study program. The subjects were classified into three groups by age and sex-corrected percentiles of fasting HDL-C and TG levels (6) from values obtained on the study diet. Group 1 had HDL-C below the 20th percentile and TG below the 90th percentile and consisted of three females and three males. Group 2 had HDL-C below the 20th percentile and TG at or above the 90th percentile, and consisted of five females and four males. Group 3, the normal control group, had an HDL-C level from the 20th to the 79th percentile and a TG level below the 90th percentile, and consisted of eight females and five males. All subjects were free from hepatic, renal, thyroid, and immunologic disorders by history and laboratory screening. 14 of the 15 low-HDL-C subjects and two of the control subjects are presented for the first time in this report. The remaining control subjects were reported in recent publications from this laboratory (7, 8) . Also, subject No. 6 (group 1) was reported in our recent study of dietary effects on HDL metabolism (8) .
Subject No. 2 (group 1) had been taking an oral hypoglycemic, glyburide, 5 mg daily for a few years at the time of the study. None of the other subjects were taking medications known to alter glucose or lipid levels. The clinical aspects of these studies were approved by the Institutional Review Board of the Rockefeller University, and informed consent was obtained from the subjects in all cases.
Apolipoprotein preparation and labeling. Apolipoproteins A-I and A-II were prepared from healthy donor plasma by ultracentrifugation, delipidation, and column chromatography using standard methods as previously described (7) . The purified apo A-I and apo A-II were radioiodinated by the iodine monochloride method and tested for pyrogenicity and sterility as outlined recently (7) .
Kinetic studies. The subjects were admitted to the Rockefeller University Hospital inpatient ward and kept on a natural food metabolic diet for 4 wk. The diet had a caloric distribution of 42% fat, 43% carbohydrate, and 15% protein. The fat content corresponded to the 50th percentile of previous American intake according to the Lipid Research Clinics study (9) , and to the 75th percentile ofthe current American consumption according to the NHANES II survey (10). The diet had a polyunsaturated-to-saturated fat (P/S) ratio of 0.1 and contained 215 mg cholesterol per 1,000 calories. Caloric need was estimated by the Harris-Benedict (11) difference between total activity and that remaining after antibody inhibition, whereas the latter was the hepatic lipase (HL) activity.
Statistical analysis. Linear regression analysis was performed using the least squares method, and statistical significance was defined as a P value < 0.05. Differences among the groups were evaluated by analysis of variance (one-way ANOVA, Neumann-Keuls' method) using the same P value cutoff. Calculations were performed on The Rockefeller University Hospital CLINFO system.
Results
The sex, age, body mass index, and lipoprotein profiles (including age and sex percentiles for HDL-C and TG) were determined for each low-HDL-C subject ( Table I ). The mean and standard deviation of these variables were calculated for low-HDL-C subjects with normal TG (group 1) and HTG (group 2), and were compared by ANOVA to that of a group of subjects with normal HDL-C and TG levels (group 3) who were studied under identical conditions (7, 8) . Because all but two of the normal-HDL-C, normal-TG subjects (group 3) have been reported previously, only the mean values for this group are given. Mean age did not differ among the groups. Variation among groups in body mass index was confined to two obese subjects (Nos. 1 and 9). Total cholesterol and LDL-C did not differ among the groups. As expected, VLDL-C was higher in the HTG subjects ofgroup 2 than in the normal-TG subjects of groups 1 and 3 (117±62 vs. 46±31 and 28±14 mg/dl, respectively, P < 0.0001). By selection, the mean HDL-C levels were lower in groups 1 and 2 compared with group 3 (35±4 and 33±6 vs. 53±9 mg/dl, P < 0.0001) with corresponding differences in HDL-C percentile (9±3 and 10±7 vs. 57±17%, P < 0.0001). Also by selection, the mean TG level of group 2 (557±392 mg/dl) and its percentile (98±2%) were much higher than values of groups 1 and 3 (levels, 128±32 and 95±31 mg/ dl, P < 0.0001; percentiles, 60±12 vs. 59±15%, respectively, P < 0.0001), which did not differ significantly from each other.
The tracer distribution volumes, apolipoprotein A-I and A-II levels, and their metabolic parameters were determined (Table II) as explained in Methods. Although the decreases in mean apo A-I level of groups 1 and 2 compared to group 3 appeared to be of unequal magnitude (106±14 and 121±13 vs. 138±19 mg/dl, decreased 23 and 12%, respectively) they were both significantly lower than group 3 (P = 0.0014 for overall difference) and they did not differ significantly from each other. The FCR ofapo A-I was equally elevated in groups 1 and 2 compared to group 3 (0.313±0.052 and 0.323±0.063 vs. 0.245±0.043 pools/d, 28 and 32% higher, respectively, P = 0.003). These relationships in overall apo A-I FCR were reflected in the plasma clearance curves of the apo A-I tracer among the members ofthe three subject groups. This is demonstrated by the curves for the three individual subjects with an FCR closest to the mean for their respective groups (Fig. 1 a) . The apo A-I TR did not differ significantly among the groups (12.5± 1.4, 12.8±0.9, and 11.5±1.9 mg/kg per d, for groups 1-3, respectively, P = 0.15). The apo A-II parameters were in higher, respectively; P = 0.006). The primary classification of subjects was by age and sexspecific percentiles, but we repeated the group comparisons after reassigning the subjects using the absolute cutoffs of 40 mg/dl for HDL-C and 200 mg/dl for TG. By these criteria, one woman (subject No. 1) was moved from group 1 to group 3, one woman (subject No. 7) moved from group 2 to group 3, and one man moved from group 3 to group 1. ANOVA ofthese absolute-cutoff groups produced only two minor changes from the original percentile-based analysis. The body mass index no longer differed among the groups, and the percent of the apo A-II label in the d > 1.21 fraction for group 1 no longer differed significantly from group 3.
To further explore the mechanisms of low HDL-C levels across the range of TG levels studied, we evaluated interrelationships among HDL-C levels, its metabolic parameters, and TG levels by linear regression analysis. HDL-C had a strong inverse correlation with the FCR of apo A-I and apo A-II (r = -0.74 for both, P < 0.0001, Fig. 2 ), but HDL-C did not correlate with apo A-I TR (r = 0.22, P > 0.1). Although HDL-C did correlate with apo A-II TR (r = 0.54, P = 0.003), this correlation explains little more than half as much of the variance in HDL-C (r2 = 0.29) as does the correlation with either FCR (r2 = 0.55). As expected, HDL-C correlated inversely with TG in single linear regression (r = -0.58, P = 0.00 1); however, in stepwise multivariate linear regression TG did not add significantly to the prediction of HDL-C variability by the FCR of apo A-I or of apo A-II.
We next tested for the reported relationship between FCR and TG (Fig. 3) . Univariate linear regression analysis revealed a positive correlation between apo A-I FCR and plasma TG (r = 0.53, P = 0.004); however, the significance of this relationship depended upon inclusion of the normal subjects (r = 0.40, P = 0. 14 with groups 1 and 2 alone). Apo A-II FCR also correlated significantly with TG levels, and this relationship was independent of the normal subject group (r = 0.65 and 0.66, P < 0.001 and P = 0.01, with and without group 3, respectively).
Given the significant differences among the three subject groups in lipase activity, the HDL/apo A-I + apo A-II ratio and density distribution of tracer, we tested for possible relationships of FCR and TR of apo A-I and apo A-II with these factors. The FCRs of apo A-I and apo A-II had inverse relationships of borderline and moderate significance, respectively, with LPL activity (r = -0.37 and -0. (a) Apo A-I tracer curves: subject 6 for group 1, subject 12 for group 2, and a male subject for group 3. (b) Apo A-II tracer curves: subject 4 for group 1, subject 11 for group 2, and a second male subject for group 3.
A-II correlated well with the LPL/HL ratio (r = -0.67 and -0.64, respectively, P < 0.001, Fig. 4) , perhaps more strongly than with HL. The TRs of apo A-I and apo A-II had an absent or borderline correlation, respectively, with LPL/HL (r = -0.1 1 and -0.36, P = 0.08 for the latter). The FCRs of apo A-I and apo A-II correlated strongly and inversely with the HDL-C/apo A-I + apo A-II ratio (r = -0.69 and -0.74 respectively, P < 0.0001, Fig. 5 ). The TRs ofapo A-I and apo A-II also had borderline and strong inverse correlations, respectively, with the HDL-C/apo A-I + apo A-II ratio (r = -0.37 and -0.67, P = 0.054 and < 0.001, respectively). The FCR, but not the TR, ofapo A-I correlated with the percent ofapo A-I tracer found in the d > 1.21 fraction (r = 0.52 and 0.21, P = 0.004 and > 0.1, respectively). In contrast, neither the FCR nor the TR of apo A-II correlated significantly with the percent of apo A-II tracer in the d > 1.21 fraction (r = 0.04 and 0.27, P > 0.1).
Due to the importance of FCR in predicting HDL-C, we explored the interrelationships ofFCR with other study parameters by stepwise multivariate linear regression analysis. The HDL-C/apo A-I + apo A-II ratio was the strongest univariate predictor of apo A-I FCR (r = -0.69, P < 0.001), and the LPL/HL ratio made the largest addition to this correlation (multiple r = 0.78, P < 0.01 for the step up). TG levels, as a third parameter, did not add significantly to this prediction of apo A-I FCR by HDL-C/apo A-I + apo A-II and LPL/HL. LPL/HL was a strong univariate predictor of apo A-I FCR (r = -0.67, P < 0.001), and plasma TG did contribute significantly to this prediction (r = 0.76, P < 0.01 for the step up). The percent of apo A-I tracer in the d > 1.21 fraction was also a univariate predictor of apo A-I FCR (r = 0.52, P = 0.004) and added significantly to the prediction of apo A-I FCR'by plasma TG (r = 0.64, P < 0.05 for the step up). Tracer distribution did not, however, add to the prediction of apo A-I FCR by LPL/ HL or HDL/apo A-I + apo A-II, separately or together.
Given the importance of the HDL-C/apo A-I + apo A-II ratio as a single and multivariate predictor of apo A-I FCR, we tested for correlations ofthis ratio with factors expected to influence HDL composition. TG was the strongest univariate predictor of HDL-C/apo A-I + apo A-II (r = -0.74, P < 0.0001). The LPL/HL ratio also was a strong univariate predictor of HDL-C/apo A-I + apo A-Il (r = 0.58, P = 0.002) and LPL/HL added strikingly to the prediction ofthat ratio by TG (r = 0.84, P < 0.01 for the step up). The percent apo A-I tracer in d > 1.21 also correlated with the HDL-C/apo A-I + apo A-Il ratio (r = -0.45, P = 0.02) but it did not add significantly to the prediction ofthis ratio by TG or LPL/HL separately or together in multivariate analysis.
Finally, we compared the female and male subjects from the low HDL-C groups. Age, BMI, and the lipid and lipoprotein values did not differ. The women had higher HDL-C levels, as expected (37±5 vs. 31±5 mg/dl, P = 0.03), although their HDL-C percentiles were not higher (8.4±5.1 vs. 10.4±5.7%, P = 0.4). Also, the women had higher levels of apo A-I (123±12 vs. 106±14 mg/dl P = 0.02) and apo A-Il (33.2±5.6 vs.
27.4±3.6, P = 0.04). Interestingly, despite these differences in the HDL-C, apo A-I, and apo A-Il levels there were no significant differences in any of the metabolic parameters (P = 0.4-0.6) nor in any ofthe other measured parameters (P = 0.2-0.9) except for a borderline significant reduction of apo A-II tracer in the d > 1.21 fraction in women (1 1.7±4.3 vs. 16 .8±5.0% for women vs. men, respectively, P = 0.06).
Discussion
The major goal of this study was to elucidate the metabolic mechanisms of low HDL-C levels. In particular we wished to explore the role of HTG, with which low HDL-C is often, but not always, associated. Six published HDL turnover studies have included three or more subjects with low HDL-C (< 20th percentile for age and sex) either with or without HTG. Three of these studies examined patients with low HDL-C and HTG (3, 4, 19) . The two studies which included normal HDL-C controls (3, 4), both found that the low-HDL-C, HTG patients had elevated FCR, in the form of either apo A-I (3) or apo A-Il (3, 4) . It was presumed that HTG was the cause of the hypercatabolism but no low HDL-C normal TG comparison group was included. Two other reports studied subjects with low HDL-C and normal TG levels (13, 20) , but neither included a HTG comparison group, and both lacked sufficient numbers either of patients or of normal HDL-C controls to draw firm conclusions regarding a metabolic mechanism.
Only one previously published study has directly addressed the question of the interaction between low HDL-C and HTG in HDL metabolism (5). Le and Ginsberg examined apo A-I turnover in seven patients with low HDL-C and normal TG, four patients with low HDL-C and elevated TG, and four subjects with normal HDL-C and normal TG. By ANOVA, the low HDL-C, normal TG group was found to have a low production (transport) rate and a normal FCR compared to controls, whereas the HTG group was found to have high TR and FCR. Although the low TR and the lack of elevated FCR in the low-HDL-C normal TG group contrast with the current paper, when we performed linear regression analysis of the data in their report, we found at least three important parallels with our own results. Their data revealed a strong inverse correlation between HDL-C and apo A-I FCR (r = -0.64, P = 0.01), a strong direct correlation between TG and apo A-I FCR (r = 0.64, P = 0.01), and the lack of a correlation between HDL-* All three groups differed C levels and apo A-I TR (r = 0.1, P = NS). By this analysis, their data support our conclusion that FCR is more important than TR in determining HDL-C levels (see below). In addition, even though by ANOVA the low-HDL-C, normal TG patients did not, as a group, have an FCR above the normal group, four of the seven individuals with low HDL-C and normal TG did have an FCR above the range ofthe normal subjects. The finding that the other three patients had a low TR as their sole HDL metabolic abnormality might be explained by differences in diet between their study and ours. Although the percent total fat was comparable between the studies, its degree ofsaturation differed substantially (P/S 0.4 vs. 0. 1). More importantly, the previous study did not employ metabolic diet conditions. We have recently demonstrated that dietary changes within the range of intake commonly seen in outpatients can have profound effects on HDL-C levels and HDL apolipoprotein metabolism (8) . On a very low fat intake, many of our normal subjects developed low-HDL-C and low-apo A-I TR without HTG, similar to the subjects in Le and Ginsberg's report. Given the relative lack of dietary control in their study, their subjects with low-HDL-C, normal TG and low-apo A-I TR may have had these findings inadvertently due' to low fat intake. An alternate explanation is that one or more of the low HDL-C normal TG group had a truly low TR, independent of diet; however, we have been unable to find any such individuals in our metabolic studies of apparently similar patients. Previously, men and women with normal HDL-C levels have been found to differ both in FCR and TR of HDL apolipoproteins (13). In our study, among control subjects the women had a lower FCR ofapo A-I and apo A-II than the men (P < 0.05 for both). In contrast, among our low-HDL-C subjects we found a striking similarity in HDL metabolism between the men and women. Despite having the expected higher levels of HDL-C, apo A-I, and apo A-II, these women had values indistinguishable from their male counterparts both for the metabolic parameters and for the other measured factors. The apparent paradox of unequal plasma levels but comparable metabolism is explained by the finding of lower plasma volume as a percent of body weight in the women (3.2±0.7% for women vs. 3.8±0.6% for men). That is, production of the same amount of HDL apolipoprotein per kilogram body weight into a smaller plasma volume resulted in higher plasma levels in the women. Thus, the mechanism of gender differences in HDL-C and apo A-I levels appears to be independent of the causes of low HDL-C levels among our hypoalphalipoproteinemic subjects. Recently, a striking parallel to this finding was reported by Melchior et al. (21) in a study of cynomolgus monkeys. Among the primates, the females' higher plasma apo A-I levels were accompanied neither by lower FCR nor by higher TR on a per kilogram basis. Rather, the female monkeys had lower plasma volume per unit body weight, similar to the low-HDL-C women in our study, and this difference alone accounted for the higher plasma levels. Thus, cynomolgus monkeys share with our low HDL-C subjects a common mechanism of gender differences HDL concentration. The metabolic parameters FCR and TR given in this study reflect only the average apo A-I and apo A-II molecule in each subject. It is, however, well established that HDL particles vary considerably in size and composition (22) . Both ofthese factors would be expected to affect the turnover of apo A-I and apo A-II. Indeed, the current study demonstrates a strong correlation between the average composition ofHDL particles and the average apolipoprotein FCR. Thus, given the compositional heterogeneity of HDL it is highly probable that HDL particles We evaluated the relationship of HDL-C to parameters of HDL apolipoprotein metabolism and related factors in subjects with low HDL-C with or without HTG. We found hypercatabolism of apo A-I to a comparable degree in both low HDL-C groups; thus, elevated FCR ofthe principal HDL apolipoprotein appears to be characteristic of low HDL-C, regardless of TG levels. On the other hand, the FCR of apo A-II was elevated significantly only in the HTG patients. Nevertheless, the prediction of HDL-C levels by apo A-I or apo A-II FCR was not enhanced significantly by the addition ofTG levels in multivariate linear regression. This suggests that the contribution of TG to control of HDL-C levels may be mediated via an effect on FCR. We found a strong positive relationship between FCR and TG by univariate linear regression analysis; however, the correlation between apo A-I FCR and TG depended upon the inclusion of the normal subjects. That is, looking solely within the low-HDL-C group, TG levels did not correlate with apo A-I FCR. In contrast, apo A-II FCR correlated with TG both with and without the normal subjects. Thus, TG levels may correlate more strongly or consistently with the FCR of apo A-Il than with the FCR of apo A-I. This suggests that plasma TG levels may have a different effect on the catabolism of HDL particles containing apo A-I and A-II compared to those containing apo A-I but not apo A-lI (22) .
Given the apparent importance of the FCR of apo A-I and apo A-Il in determining HDL-C levels, we carefully explored potential determinants of FCR in addition to plasma TG levels. Two indices of HDL composition, the HDL-C/apo A-I + apo A-Il ratio, and the percent of apo A-I tracer in the d > 1. 21 fraction, both correlated strongly with the apo A-I FCR, inversely and directly, respectively. We previously found an inverse correlation between FCR and the HDL-C/apo A-I + apo A-II ratio in women with high HDL-C levels (7) , similar to the correlation in this report. That study and this one together strongly suggest that HDL composition is an important determinant of FCR across the usual range of HDL-C levels. The single best predictor of apo A-I FCR was the HDL-C/apo A-I + apo A-Il ratio. This ratio, in turn was best predicted (over 70% of the variability in multiple linear regression) by TG and LPL/HL. The LPL/HL ratio highlights reciprocal changes in LPL and HL activity. A recent population-based study found reduced LPL and increased HL activities in subjects with low HDL-C (17) . Elevated HDL composition, which appears to be a major determinant of apo A-I and apo A-II FCR, which, in turn, may determine HDL-C levels (see Fig. 6 ). The dual contribution by TG levels and the LPL/HL ratio to HDL composition may explain an apparent paradox in our results. Although HTG contributes to low HDL-C by elevating FCR, subjects with normal TG may still have low HDL-C and rapid FCR if they have non-TG-dependent mechanisms capable of producing abnormalities in HDL composition to a degree similar to that of HTG patients.
In summary, we have demonstrated that high apo A-I and apo A-II FCR is the major metabolic mechanism of low HDL-C, regardless of the presence or absence ofHTG. Nevertheless, HTG can contribute to lowering of HDL-C levels, and this may occur via an effect of TG levels on FCR. The promotion of FCR by HTG may be additive to the effect of a low LPL/HL ratio, and both of these factors appear to be mediated through lipid depletion of HDL. Given the importance of low HDL-C levels as predictors of atherosclerosis risk, we suggest that elevated FCR of apo A-I and apo A-II may constitute an important metabolic mechanism underlying such a susceptibility. Furthermore, as potential determinants of FCR, TG levels, postheparin lipase activity, and HDL composition may also play important mechanistic roles in atherogenesis. 
